^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Proton pump inhibitor

    Related drugs:
    2d
    A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old (clinicaltrials.gov)
    P2, N=76, Active, not recruiting, Takeda | Recruiting --> Active, not recruiting
    Enrollment closed
    4d
    The Effect of PPI on Endoscopic Treatment of WON: a Multicenter Randomized Controlled Trial. (clinicaltrials.gov)
    P=N/A, N=120, Not yet recruiting, Qilu Hospital of Shandong University
    New trial
    4d
    FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2030 --> Mar 2028
    Trial completion date
    |
    docetaxel • cabazitaxel • omeprazole
    14d
    A Trial of Omeprazole and Low Dose Aspirin to Identify Colorectal Biomarkers of Preventive Efficacy (clinicaltrials.gov)
    P1, N=21, Completed, University of Michigan Rogel Cancer Center | Recruiting --> Completed | Trial completion date: Sep 2026 --> Feb 2026
    Trial completion • Trial completion date
    |
    omeprazole
    15d
    Tegoprazan-Based Dual Therapy With Amoxicillin vs Tetracycline for H. Pylori Eradication (clinicaltrials.gov)
    P=N/A, N=600, Completed, Zhongshan Hospital (Xiamen), Fudan University | Recruiting --> Completed | N=87 --> 600
    Trial completion • Enrollment change
    21d
    A Randomized, Three-Arm Study Comparing Vonaprazan 10 mg, Vonaprazan 20 mg, and Esomeprazole 40 mg for the Healing of LA Grade B or Higher Reflux Esophagitis at 8 Weeks (clinicaltrials.gov)
    P=N/A, N=414, Recruiting, Asian Institute of Gastroenterology, India | Initiation date: Jun 2025 --> Dec 2025
    Trial initiation date
    22d
    Efficacy and Safety of Tegoprazan Dual Therapy and Furazolidone-based Bismuth Quadruple Therapy for Helicobacter Pylori Eradication: A Prospective, Multicenter, Open-label, Randomized Controlled Clinical Study (clinicaltrials.gov)
    P=N/A, N=400, Completed, Nanjing First Hospital, Nanjing Medical University | Not yet recruiting --> Completed | N=600 --> 400 | Trial completion date: Dec 2024 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    24d
    A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants (clinicaltrials.gov)
    P1, N=48, Recruiting, Genentech, Inc. | Trial completion date: Feb 2026 --> Aug 2026 | Trial primary completion date: Feb 2026 --> Aug 2026
    Trial completion date • Trial primary completion date
    |
    perzebertinib (RG6596)
    28d
    Vonoprazan Test for PPI Refractory GERD (clinicaltrials.gov)
    P=N/A, N=100, Enrolling by invitation, Fu Jen Catholic University Hospital
    New trial
    1m
    Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial (clinicaltrials.gov)
    P=N/A, N=4824, Not yet recruiting, Fudan University | Initiation date: Dec 2025 --> Mar 2026
    Trial initiation date
    1m
    Weimishu prescription alleviates liver-stomach disharmony and chronic gastritis by reducing inflammation and regulating gastric stem cell differentiation. (PubMed, J Tradit Chin Med)
    WMSP ameliorated gastric mucosal injury in CG-LSD rats by regulating the NF-κB/β-catenin signaling pathway, thereby suppressing inflammation and promoting gastric stem cell differentiation. These findings highlight the therapeutic potential of WMSP, providing the foundation for further clinical evaluations of WMSP in CG-LSD treatment.
    Journal
    |
    CDH1 (Cadherin 1) • SOX2 • LGR5 (Leucine Rich Repeat Containing G Protein-Coupled Receptor 5)
    |
    omeprazole
    1m
    Case Report: Cystic fibrosis transmembrane conductance regulator gene heterozygous variation presenting with abdominal pain and hepatopancreatic lesions in a child. (PubMed, Front Pediatr)
    Treatment with octreotide, omeprazole, and pancreatic enzyme replacement therapy led to symptom resolution...The clinical manifestations of CF are diverse, and digestive tract symptoms are common; therefore, early identification and diagnosis are required. As chr7: 117250723 G > T may be a pathogenic gene, long-term follow-up is needed.
    Journal
    |
    CFTR (CF Transmembrane Conductance Regulator)
    |
    omeprazole